MiMe-A: Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

• Sponsor: Jules Bordet Institute (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT03339843
• Collaborator: Eli Lilly and Company (Industry)
• Enrollment: 85
• Locations: 11
• Arm: 1
• Anticipated Duration (Months): 51
• Patients Per Site: 7.7
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria.

Based on the rate of FDG-avidity and the absence of deactivation of the Rb gene function in more than 95% of cases, we propose to define 5 tumour types of interest in a preliminary stage:

1. Platinum-refractory esophageal adenocarcinoma (ADC)

2. Platinum-refractory esophageal squamous cell carcinoma (SCC)

3. Platinum-refractory cholangiocarcinoma

4. Platinum-refractory and progressive after immunotherapy urothelial cancer

5. Platinum-refractory endometrial cancer

Condition or Disease	Intervention/Treatment	Phase
Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer	Drug: Abemaciclib	Phase 2

Detailed Description

In various solid tumour types FDG-PET/CT has been shown to identify treatment-refractory diseases with a high negative predictive value (NPV) through a whole-body quantitative assessment of treatment-induced changes in tumour glucose uptake soon after treatment initiation, before any structural changes are observed. Progress in the standardisation of FDG-PET/CT imaging and response analysis now allow its use in multicentric trials opening the possibilities for trials where treatment allocation will be based on early metabolic response. MiMe has been built on the assumption that a medication which does not induce any metabolic changes in a given clinical setting is unlikely to induce a significant benefit and does consequently not deserve further investigation as a single agent in this setting.

MiMe, by assessing metabolic response early during the treatment course, will hopefully provide useful information about the drug activity in various cancer types, and about mechanisms of resistance through a potential ambitious translational research program with serial collection of circulating-tumour DNA (ct-DNA).

Study Design

• Study Type: Interventional
• Actual Enrollment: 85 participants
• Allocation: N/A
• Intervention Model: Sequential Assignment
• Intervention Model Description: This is a two step, open-label, basket trial looking at 5 different tumour types.This is a two step, open-label, basket trial looking at 5 different tumour types.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
• Actual Study Start Date: Dec 19, 2018
• Actual Primary Completion Date: Nov 12, 2021
• Anticipated Study Completion Date: Mar 21, 2023

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Abemaciclib This study contains 2 stages; during the 1st stage, a maximum of 17 patients will be enrolled in each tumour type cohort. After 13 evaluable patients have been enrolled, an interim analysis will be performed. If 3 or more patients are seen to have experienced a treatment success, then the cohort will pass into the 2nd stage in which a maximum of 20 more patients are enrolled. If 2 or less patients are seen to have experienced a treatment success, then that cohort will be closed and will not proceed into the 2nd stage. Subjects will receive 200 mg of abemaciclib orally, twice a day, during cycles of 28 days each. The subject will undergo: A baseline FDG-PET/CT and a baseline CT scan and A blinded early FDG-PET/CT at D14 +/- 2 days of study treatment. A treatment success is defined as a patient who has metabolic response according to PERCIST with a response cut off set at 15% at the early FDG-PET/CT and a morphological disease control after 2 cycles measured by RECIST v1.1.

Drug: Abemaciclib; Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.; Other Names: FDG-PET/CT

Outcome Measures

Primary Outcome Measures

1. Evaluate the anti-tumour activity of abemaciclib in the five tumour types studied in this trial using FDG-PET/CT during the first cycle of therapy (early FDG- PET/CT). [2 months]

   Therapy success rate defined as: PERCIST 15%-assessed Metabolic Response at early FDG-PET/CT (D12-D16)

2. Evaluate the anti-tumour activity of abemaciclib in the five tumour types studied in this trial using RECISTv1.1 after 2 cycles of therapy as a screening tool. [2 Months]

   Therapy success rate defined as: RECISTv1.1-assessed Disease Control (DC) after 2 treatment cycles (CR or PR or SD)

Secondary Outcome Measures

1. Evaluate Progression-free survival (PFS define as the time from treatment start until disease progression or death) at 24 weeks from treatment start [6 months]

   RECIST v1.1-based radiological response assessment performed at 24 weeks from the treatment start to determine the PFS

2. Evaluate Overall Survival (OS defined as the time from treatment start until death) at 24 weeks from treatment start [6 months]

   RECIST v1.1-based radiological response assessment performed at 24 weeks from the treatment start to determine the OS.

3. To evaluate median progression-free survival (PFS) [42 months]

   Progression Free Survival

4. Evaluate median overall survival (OS) [42 months]

   Overall Survival

5. To evaluate toxicity profile [6 months]

   Toxicity profile according to CTCAE version 4.03

6. Evaluate the correlation of early metabolic response using FDG-PET/CT with morphological response to treatment assessed by RECIST [6 months]

   RECIST v1.1-based radiological response assessment performed at 24 weeks from the treatment start to determine the PFS and OS

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Age ≥ 18 years old

2. Female or male

3. ECOG performance status ≤ 1

4. Life expectancy of greater than 12 weeks

5. Must have histologically confirmed cancer corresponding to the predefined tumour subtypes (esophageal adenocarcinoma, esophageal squamous cell carcinoma, cholangiocarcinoma, urothelial cancer (progressive after immunotherapy), endometrial cancer) and metastatic or non-resectable and refractory to standard platinum regimens (and progressive after immunotherapy for the urothelial cancer).

6. Presence of at least one metabolically measurable tumour lesion on FDG-PET/CT, according to PERCIST. If previously irradiated, must have been more than 2 months before the baseline FDG PET/CT.

7. Measurable disease according to RECIST v 1.1

8. Serum pregnancy test (for subjects of childbearing potential) negative

9. Women of childbearing potential must agree to the use a highly effective method of contraception prior to study entry, during the course of the study and at least 3 months after the last administration of study treatment.

10. Men with childbearing potential partner must agree to use condom during the course of this study and for at least 3 months after the last administration of the study treatment.

11. Adequate coagulation: International Normalized Ratio (INR) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy as long as INR and activated partial thromboplastin time [aPTT] are within therapeutic range of intended use of anticoagulants

12. Adequate bone marrow function as defined below:

• Hemoglobin ≥ 10 g/dL

• Absolute neutrophil count ≥ 1500/µL or 1.5x109/L

• Platelets ≥ 100000/µL or 100x109/L

• Leukocytes ≥ 3,000/µL

1. Adequate liver function as defined below:

• Serum total bilirubin within 1.5 × normal institutional limits (except for Gilbert syndrome where direct bilirubin should be <1.5 institutional ULN)

• AST/ALT/ALP) levels < 3 × institutional upper limit of normal (or ALT and AST <5 times upper limit of normal if liver metastases are present).

1. Adequate renal function as defined below: Cockcroft-Gault creatine clearance >50ml/min

2. Completion of all necessary screening procedures

3. Ability to swallow capsules

4. Grade ≤ 1 toxicity due to any previous cancer therapy according to the National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE, v.4.03). Grade 2 is allowed in case of alopecia and peripheral sensory neuropathy

5. Availability of primary archived tumour tissue block (1 FFPE tumour tissue)

6. Signed Informed Consent form (ICF) obtained prior to any study related procedure

Exclusion Criteria:

1. Subjects meeting one of the following criteria are not eligible for this studyParticipants who have had chemotherapy, radiotherapy, immunotherapy, or targeted therapy within 3 weeks prior study enrolment

2. Participants receiving concomitantly any other experimental agents

3. Patients who have received prior therapy with other CDK4/6 inhibitors

4. Subjects with known brain metastasis; unless the metastasis are asymptomatic and have been stable since at least 2 months prior to treatment start.

5. Patient with meningeal carcinomatosis

6. Have had major surgery within 28 days prior to the start of the treatment to allow for post-operative healing of the surgical wound

7. History of allergic reactions attributed to compounds of similar chemical or biologic composition

8. Bleeding diathesis, thromboembolic event, history of cardiovascular ischemic disease or cerebrovascular incident within the last six months

9. Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia

10. Substance abuse, psychiatric illness/social situations, any psychological, familial, sociological, geographical condition, significant medical or surgical condition currently uncontrolled by treatment that would limit compliance with study requirements or interfere with the patient's ability to understand informed consent and participation in the study

11. Pregnant and/or lactating women

12. Uncontrolled Diabetes

13. Known history of HIV infection, or active hepatitis B or C requiring treatment with anti-viral therapy

14. Have received recent (within 28 days prior the enrolment) yellow fever vaccination

15. Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free and are deemed by the investigator to be at low risk for recurrence of that malignancy.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Universitair Ziekenhuis	Antwerpen		Belgium
2	Institut Jules Bordet	Bruxelles		Belgium	1000
3	Algemeen Ziekenhuis Groeninge	Kortrijk		Belgium	8500
4	CHC Saint-Joseph	Liège		Belgium	4000
5	CHU Ambroise Paré	Mons		Belgium	7000
6	CHU UCL Namur Sainte-Elisabeth	Namur		Belgium	5000
7	Centre Oscar Lambret	Lille		France	59000
8	Institut Paoli-Calmettes	Marseille		France	13009
9	Centre Henri Becquerel	Rouen		France	76038
10	Hôpital universitaire de Strasbourg - ICANS	Strasbourg		France	67000
11	IUCT Oncopole - Institut Claudius Regaud	Toulouse		France	31059

Sponsors and Collaborators

• Jules Bordet Institute
• Eli Lilly and Company

Investigators

• Study Chair: Laura Polastro, MD, Jules Bordet Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jules Bordet Institute
• ClinicalTrials.gov Identifier: NCT03339843
• Other Study ID Numbers: IJB-MULTI-MIME-A-2017
• First Posted: Nov 13, 2017
• Last Update Posted: May 31, 2022
• Last Verified: May 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Jules Bordet Institute: cancer
• Additional relevant MeSH terms: Endometrial Neoplasms; Cholangiocarcinoma

Study Results

No Results Posted as of May 31, 2022